Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses drugs with anti-androgenic effects and their mechanisms but reports no new research findings.

This review discusses the role of primary and secondary factors in androgenetic alopecia, suggesting that plant-based folk remedies may ameliorate these factors when used alongside conventional therapies; it reports no new clinical results.

This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.

Topical treatment SM04554 safely promotes hair growth in male baldness.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

This study found that using hollow mesoporous silica nanoparticles as carriers in a topical finasteride formulation significantly enhanced drug retention and hair regrowth in an AGA mouse model, suggesting a promising approach for treating androgenetic alopecia with reduced side effects.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

In this chemical investigation, cyclospongiaquinone 1 from the sponge Verongula cf. rigida showed strong steroid 5α-reductase inhibitory activity, comparable to that of finasteride.

This study observed that males with androgenetic alopecia using dutasteride showed significantly improved COVID-19 outcomes, including shorter duration of symptoms and viral shedding, compared to those not using it and non-AGA males.

In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.

This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

In this study, researchers explored whether minoxidil, a common treatment for androgenetic alopecia, may have estrogenic activity and found preliminary evidence suggesting it could act as a partial agonist of Estrogen Receptor α (ERα).

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

Dutasteride is more effective than finasteride for hair growth with similar side effects.

This study found that oral finasteride improved hair growth and reduced hair shedding in male patients with androgenetic alopecia, with no significant side effects observed.

This study found that a topical formulation with nanostructured lipid carriers containing finasteride significantly restored hair follicles in androgenetic alopecia-induced rats without systemic absorption, suggesting its potential for safer and effective AGA treatment.

This study describes the synthesis of finasteride from 4-androstene-3,17-dione in a seven-step process with an overall yield of 18.6%.

This study reported that polysaccharides from Astragalus roots could promote hair regeneration and optimize drug delivery when combined in innovative microneedles, effectively improving hair growth in mice with androgenetic alopecia.

This review discusses the application of transdermal drug delivery systems for androgenetic alopecia and explores new technologies to enhance drug penetration but reports no clinical results.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

This article discusses various treatments for androgenetic alopecia and reports no new clinical results, noting the condition's aesthetic and psychological impact.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.

This study found that Ishophloroglucin A from brown seaweed may treat androgenic alopecia by inhibiting 5α-reductase and promoting hair growth-related factors in human dermal papilla cells.